A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma.
Di Meo F, Iyer A, Akama K, Cheng R, Yu C, Cesarano A, Kurihara N, Tenshin H, Aljoufi A, Marino S, Soni RK, Roda J, Sissons J, Vu LP, Guzman M, Huang K, Laskowski T, Broxmeyer HE, Roodman DG, Perna F.
Di Meo F, et al.
Cell Rep Med. 2023 Jul 18;4(7):101110. doi: 10.1016/j.xcrm.2023.101110.
Cell Rep Med. 2023.
PMID: 37467717
Free PMC article.